Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2025)

Monopar Therapeutics has disclosed Share-based Compensation across 9 years of filings, most recently posting -$3.7 million for Q4 2025.

• Share-based Compensation for Q4 2025 came in at -$3.7 million, down 1440.13% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.2 million (down 253.47% YoY), and the FY2024 annual result was $1.1 million, down 39.89% from the prior year.
• Share-based Compensation came in at -$3.7 million for Q4 2025 at Monopar Therapeutics, down from $617413.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q1 2025 to a low of -$3.7 million in Q4 2025.
• The 5-year median for Share-based Compensation is $357593.0 (2021), against an average of $178382.8.
• Peak annual rise in Share-based Compensation reached 4469.37% in 2025, while the deepest fall reached 1440.13% in 2025.
• Monopar Therapeutics' Share-based Compensation stood at $392065.0 in 2021, then gained by 0.34% to $393417.0 in 2022, then gained by 20.54% to $474206.0 in 2023, then slumped by 41.25% to $278612.0 in 2024, then slumped by 1440.13% to -$3.7 million in 2025.
• The last three Share-based Compensation figures came in at -$3.7 million (Q4 2025), $617413.0 (Q3 2025), and $567957.0 (Q2 2025), per Business Quant data.